Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MILLENNIUM PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1993-01-01

Employees: 1K

Market Cap: -

Website: http://www.takedaoncology.com

Clinical Trials

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: VELCADE
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2009-12-30

Last Posted Date: 2014-01-13

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 164

Registration Number: NCT01040871

Locations: 🇧🇪
Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Gent, Belgium

Dose Escalation Study of MLN4924 in Adults With Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: MLN4924

First Posted Date: 2009-11-11

Last Posted Date: 2013-07-16

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 37

Registration Number: NCT01011530

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Santa Monica, California, United States

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib citrate

First Posted Date: 2009-08-24

Last Posted Date: 2018-01-10

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT00963820

Locations: 🇺🇸
Mayo Clinic- Scottsdale, Scottsdale, Arizona, United States
🇺🇸
James R. Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 3 locations

Study of MLN8237 in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Alisertib

First Posted Date: 2009-08-19

Last Posted Date: 2019-03-12

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 53

Registration Number: NCT00962091

Locations: 🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica, California, United States

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Phase 1

Completed

Conditions: Advanced Non-hematologic Malignancies
Advanced Metastatic Melanoma

Interventions: Drug: TAK-733

First Posted Date: 2009-07-29

Last Posted Date: 2013-07-02

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 51

Registration Number: NCT00948467

Locations: 🇺🇸
Wayne State University Karmanos Cancer Institute, Detriot, Michigan, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Advanced Solid Tumors
Lymphoma

Interventions: Drug: TAK-901

First Posted Date: 2009-07-09

Last Posted Date: 2011-12-08

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 20

Registration Number: NCT00935844

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Phase 1

Completed

Conditions: Relapsed and Refractory Multiple Myeloma

Interventions: Drug: Ixazomib

First Posted Date: 2009-07-03

Last Posted Date: 2019-08-07

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT00932698

Locations: 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Phase 2

Completed

Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

Interventions: Drug: Rituximab
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2009-07-02

Last Posted Date: 2017-01-11

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 206

Registration Number: NCT00931918

Locations: 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
Fountain Valley Regional Hospital, Fountain Valley, California, United States
🇺🇸
St. Jude Heritage Healthcare, Fullerton, California, United States

and more 67 locations

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: MLN4924
Drug: Azacitidine

First Posted Date: 2009-06-01

Last Posted Date: 2013-12-05

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 72

Registration Number: NCT00911066

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, Illinois, United States
🇺🇸
Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States

and more 3 locations

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

Phase 1

Withdrawn

Conditions: Glioblastoma Multiforme

Interventions: Drug: Tandutinib, bevacizumab, and temozolomide

First Posted Date: 2009-05-20

Last Posted Date: 2009-05-20

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT00904852

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy